- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Health Highlights: Jan. 18, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Gluten-Free Chicken Nuggets Recalled by Perdue Foods
Possible wood contamination has led to the recall of more than 68,000 pounds of gluten-free chicken nuggets from Perdue Foods, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) says.
The agency said there are no confirmed cases of illness linked with the ready-to-eat chicken nuggets, which were produced on Oct. 25, 2018, CNN reported.
“The problem was discovered when the firm received three consumer complaints that wood was found in the product,” according to a FSIS statement.
The agency said that consumers with the recalled chicken nuggets should throw them away or return them to the place of purchase, CNN reported.
——
FDA Panel Splits Vote on New Diabetes Drug
A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.
Despite that result, the FDA is expected to decide by the end of March whether the drug — sotagliflozin (Zynquista) should be made available in the United States, The New York Times reported.
The drug, used along with insulin, is a once-daily pill meant to help type 1 diabetes patients manage their blood sugar levels.
Some of the advisory panel members voted against Zynquista because it carries an increased risk of a dangerous condition called diabetic ketoacidosis, which occurs when the body doesn’t get enough insulin, The Times reported.
Drug makers Sanofi and Lexicon Pharmaceuticals said they’ll continue to work with the FDA through the review process for the drug.
Copyright © 2024 HealthDay. All rights reserved.